Figure S10 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types

Q: What type of study is this?

This is a Experimental Study study.

Zahra Davoudi; Thomas S. Dexheimer; Nathan P. Coussens; Thomas Silvers; Raymond G. Fox; Samantha B. Kemp; Punita Juneja; Joel Morris; Melinda G. Hollingshead; Naoko Takebe; James H. Doroshow; Beverly A. Teicher

doi:10.1158/2767-9764.30304720

October 8, 2025

Figure S10 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types

View Full Paper

Ask AI

Bookmark

Share

Key Points

Combination therapy utilizing bi-3406 and nintedanib reduces tumor viability in multicell-type tumor spheroids derived from various cancers.
Key findings reveal a significant reduction in tumor mass when both drugs are combined, indicating a potential therapeutic synergy.
Analysis conducted through experimental study on patient-derived multicell-type tumor spheroids to validate drug efficacy.
These insights could lead to new treatment strategies for patients with oncogenic kras variants across multiple cancer types.

Implication

Combination therapy utilizing ras pathway inhibitors shows activity in multicell-type tumor spheroids, suggesting innovative approaches in cancer treatment.

Abstract

Figure S10. Combination activity of BI-3406 with nintedanib in multicell-type tumor spheroids.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Davoudi et al. (2025) studied this question.

synapsesocial.com/papers/68e861857ef2f04ca37e3b9d https://doi.org/10.1158/2767-9764.30304720

View Full Paper

Ask AI

Bookmark

Share

Figure S10 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types

Key Points

Implication

Abstract

Discussion

Cite This Study

Figure S10 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading